Ymmunobio
PrivateLast Round
Grant
Jan 23, 2025
Total Funding Raised
$1.93M
Company Overview
Ymmunobio operates in Healthcare & Life Sciences and is based in Riehen. Its latest recorded funding round was a Grant round in January 2025.
Ymmunobio is a drug discovery company developing first-in-class antibody-based therapies for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ymmunobio Comparables
Compare Ymmunobio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gilead Sciences | 81% | |
| Taiho Pharmaceutical Co., Ltd. | 77% | |
| Sotio | 77% |
For institutional investors. Book with your work email.
Ymmunobio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 23, 2025 | ||||
| Seed | Nov 13, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ymmunobio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OKG Capital | Seed |
| Innosuisse | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 29, 2025
Co-developing advanced liquid biopsy with EVIIVE for NPTXR detection.
- Nov 29, 2025
Partnering with EVIIVE on advanced liquid biopsy for cancer detection.
For institutional investors. Book with your work email.
Ymmunobio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ymmunobio's valuation, stock price, and market status.
Is Ymmunobio a public or private company?
Ymmunobio is a private company.
What is the current stock price of Ymmunobio?
Ymmunobio is a private company, so its shares have no public market price. Caplight tracks Ymmunobio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ymmunobio worth (valuation)?
Valuation information for Ymmunobio is not publicly available.
Can I buy Ymmunobio stock?
Ymmunobio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ymmunobio's last funding round?
Ymmunobio's most recent funding round was Grant on January 23, 2025.
Who are the main investors in Ymmunobio?
Key investors in Ymmunobio include OKG Capital, Innosuisse.
Will Ymmunobio IPO soon?
No public IPO plans have been announced for Ymmunobio.
How can I track Ymmunobio secondary market activity?
Caplight tracks bids, offers, and trades in Ymmunobio's shares on secondary markets.